Clinical Trials

April 11, 2012

Clinical Study with ACT-293987 in Patients with Pulmonary Arterial Hypertension

Start Date: 12/2009

End Date: 08/2013

Design: Placebo-controlled, Background treatment allowed

Age range (years): from 18 to 75

Type of PH

PAH belonging to the following subgroups of the updated Dana Point Clinical Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or Associated (APAH) with Connective tissue disease, Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair or HIV infection)

Study Duration for individual patient: Baseline (day 1) to over a period of up to 3.5 years

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.